Dr Reddys promoters report no share encumbrance in FY26

1 min read Updated on 13 Jun 2026, 07:02 AM

Reviewed by

Ashish TScanX News Team

AI Summary

Dr Reddys Laboratories disclosed that its promoters and persons acting in concert did not create any encumbrance on the company's shares during FY26. The declaration was submitted to the stock exchanges pursuant to SEBI regulations.

*this image is generated using AI for illustrative purposes only.

Dr Reddys Laboratories has confirmed that its promoters and persons acting in concert did not create any encumbrance on the company's shares during FY26. This disclosure, made to the National Stock Exchange of India and BSE Limited, ensures compliance with regulatory transparency requirements regarding shareholding by key stakeholders.

The declaration was submitted pursuant to Regulation 31(4) and (5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The filing confirms that neither the promoter group nor persons acting in concert pledged or encumbered shares directly or indirectly throughout the financial year.

The disclosure was signed by Kallam Satish Reddy and G V Prasad on behalf of the promoter group. The list of promoters and persons acting in concert includes key individuals and family trusts associated with the company's leadership.

Promoters and Persons Acting in Concert

Name	Name
G. V. Prasad	Satish Reddy Kallam
Anuradha Gunupati	Deepti Reddy Kallam
APS Trust	VSD Holdings & Advisory LLP
Kallam Satish Reddy (HUF)	G. Vani Sanjana Reddy
Gunupati Mallika Reddy	Gunupati Venkateshwara Prasad (HUF)
Sharathchandra Reddy Gunupati	K Shravya Reddy
K Vishal Reddy	GVP Family Trust
Malli G Family Trust	Serendipity Family Trust
SRG Family Trust	VSD Family Trust
SKR Family Trust	KVR Family Trust

Historical Stock Returns for Dr Reddys Laboratories

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.05%	+0.62%	-0.35%	+0.15%	-5.60%	+16.94%

How will the absence of share encumbrance impact Dr. Reddy's Laboratories' ability to raise capital for future acquisitions?

What does this disclosure signal about the promoters' long-term confidence in the company's growth strategy?

Could this clean shareholding structure make Dr. Reddy's a more attractive target for strategic partnerships or M&A activity?

Read Next Article

Dr. Reddy's management to meet investors in London on June 16-17

0 min read Updated on 11 Jun 2026, 02:01 AM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

Dr. Reddy's Laboratories Limited announced that its management will participate in analyst and institutional investor meetings in London on June 16 and June 17, 2026. Organized by Investec, these in-person group meetings are part of the company's investor relations activities under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule is subject to change based on exigencies.

*this image is generated using AI for illustrative purposes only.

Dr. Reddy's Laboratories Limited has announced that its management will engage with analysts and institutional investors during a conference in London on June 16 and June 17, 2026. The meetings are organized by Investec and will provide a platform for the company to interact with single institutions and investor groups.

The interaction is part of the company's ongoing investor relations activities under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR, signed the intimation on June 10, 2026.

The schedule for the meetings is detailed below: